JOHNSON & JOHNSON

& Johnson Johnson has an estimated net worth of $4.15 Billion. This is based on reported shares across multiple companies, which include CVRx, Inc., Fusion Pharmaceuticals Inc., Provention Bio, Inc., Inspire Medical Systems, Inc., ACHILLION PHARMACEUTICALS INC, Minerva Neurosciences, Inc., Protagonist Therapeutics, Inc, AQUINOX PHARMACEUTICALS, INC, NEVRO CORP, Aldeyra Therapeutics, Inc., GENOCEA BIOSCIENCES, INC., TENGION INC, BARRIER THERAPEUTICS INC, IMMUNICON CORP, CRITICAL THERAPEUTICS INC, UNIVERSAL BIOSENSORS INC, EXEGENICS INC, ANIMAS CORP, CLOSURE MEDICAL CORP, Kenvue Inc., MeiraGTx Holdings plc, and Contineum Therapeutics, Inc..

2023 was & Johnson Johnson's most active year for disposing of shares, totalling 1 transactions. & Johnson Johnson's most active month to dispose stocks was the month of July. In 2023 & Johnson Johnson cashed out on 1,533,830,450 shares for a total of $0.00, their largest year based on trade value.